Prothena carefully explains why it's killing a psoriasis drug after PhIb
Prothena is cutting its losses on one of its key drug development programs after concluding their therapy failed to pass muster in a Phase Ib study of psoriasis.
PRX003 hit its mark — CD146 — on Th17 cells, as they expected. But researchers didn’t see the kind of pharmacodynamic effect they were looking for. So there will be no Phase II to come in either psoriasis or atopic dermatitis, two ailments which have seen considerable progress recently from newly approved therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
